Thursday, February 7, 2:32 PM
RTI Biologics (RTIX -12.7%) gets smacked today after its Q4 EPS came in-line with forecasts, but revenue misses analyst estimates on weakness in its surgical specialties and sports medicine businesses. The company also issued downbeat guidance, saying sales and profit during the first half of the year will be weak due to customer reaction to its FDA warning letter over contaminated human tissue implants.
Comment![Healthcare, Earnings, On the Move]
Thursday, April 26, 2012, 11:43 AMRegeneration Technologies (RTIX): Q1 EPS of $0.04 beats by $0.01. Revenue of $43.7M (+7.6% Y/Y) beats by $1.8M. (PR)
Tuesday, January 31, 2012, 4:05 PM
RTI Biologics (RTIX -13.5%) trades down into the close despite beating Q4 estimates. Profit actually declined 5.5% Y/Y due to inventory issues, which masked a 20% jump in international sales. The company warns on FY12 guidance however, now saying it expects revenue in the range of $174M - $176M. Analysts are looking for sales of $176M.
Comment![On the Move, Healthcare]
Tuesday, January 31, 2012, 8:08 AMRegeneration Technologies (RTIX): Q4 EPS of $0.04 beats by $0.01. Revenue of $42.9M (-5.5% Y/Y) beats by $1.5M. (PR)